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Abstract 
Purpose: To ascertain the effect of perioperative application of high-dose of finasteride on prostate-
specific antigen (PSA) in serum, tumor necrosis factor α (TNF-α) and interleukin-1β (IL-1β) in prostatic 
fluid of prostatic hyperplasia (BPH) patients with transurethral plasmakinetic resection of prostate 
(PKRP).  
Methods: In total, 141 BPH patients treated with PKRP in Hunan Provincial People’s Hospital, 
Changsha City, China from January 2015 to January 2017 were randomly divided into three groups of 
47 cases each, viz, high-dose (10 mg of finasteride), low-dose (5 mg of finasteride), control (0 mg of 
finasteride). The levels of PSA in serum, as well as the levels of TNF-α and IL-1β in prostatic fluid were 
evaluated 7 days before and after surgery. Re-bleeding within 3 months after surgery in the three 
groups were performed and the patients observed.  
Results: Intra-operative bleeding volume, bleeding volume per unit resected tissue, and intra-operative 
volume of rinsing fluid were significantly less in high- and low-dose groups than those in the control 
group (p < 0.05); furthermore, the operation time was significantly shorter than that for the control group 
(p < 0.05). Seven days after surgery, international prostate symptom score (IPSS), serum PSA, and 
TNF-α and IL-1β in prostatic fluid of the high- and low-dose groups were significantly lower than those of 
the control group (p < 0.05). Also, maximum urine flow rate was significantly higher than that of the 
control group. Serum PSA, and TNF-α and IL-1β levels in prostatic fluid were significantly lower than 
those of low-dose group (p < 0.05). Serum PSA as well as TNF-α and IL-1β levels in prostatic fluid were 
positively correlated with IPSS score (r = 0.817, 0.838, 0.859, p < 0.001). The admission rate due to re-
bleeding was lowest in the high-dose group, followed by the low-dose group.  
Conclusion: Finasteride combined with PKRP for BPH acts synergistically to reduce serum PSA levels 
and local inflammatory reaction. High-dose finasteride/PKRP combination is more efficacious than the 
low-dose combination, thereby improving short-term prognosis in patients. 
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Benign prostate hyperplasia (BPH) is one of the 
common diseases in middle-aged males. The 
number of cases is increasing every year in 
tandem with rapid increase in number of aging 
people worldwide [1,2]. Transurethral 
plasmakinetic resection of prostate (PKRP) is a 
new surgical technique that has emerged in 
recent years [3]. Compared with the traditional 
transurethral resection of prostate, PKRP 
effectively reduces bleeding and transurethral 
resection syndrome [4], and so it is currently one 
of the reliable regimes for BPH.  
 
Previous studies [5] considered the possibility 
that intraoperative and postoperative bleeding 
would occur easily in PKRP, which would affect 
the prognosis of patients, but finasteride was 
introduced to inhibit neovascularization and 
reduce blood flow in BPH, thereby preventing 
bleeding [6,7]. Thus, it was recommended that 
this drug should be used in the perioperative 
period. However, the effectiveness of finasteride 
in BPH treatment is associated with its inhibition 
of angiogenesis, and negative its effect on local 
anti-inflammatory agents [8,9]. However there 
are few reports on the impact of administration of 
finasteride in the perioperative period on the 
serum levels of inflammatory factors of patients. 
 
Another impediment to the current use of 
finasteride is the issue of the dose regime of the 
drug in the perioperative period which has not 
been fully standardized. Furthermore, the best 
dose of the drug to be administered has not been 
made clear. On account of these shortcomings, a 
randomized controlled investigation was 
conducted in this study to unravel the curative 
effect of different doses of finasteride combined 
with PKRP in treating BPH, and its impact on 
prostate specific antigen (PSA) and serum 






The study was conducted in 141 patients with 
BPH treated in Hunan Provincial People’s 
Hospital from January 2015 to January 2017. 
The study was approved by the Ethics 
Committee of Hunan Provincial People’s Hospital 
(approval no. 20141201), and followed the 
guidelines of Declaration of Helsinki [10]. The 
study randomly divided all the patients into three 
groups, each of 47 patients. The high dose group 
received high finasteride dose, while the low-
dose group received a lower dose of finasteride. 





(1) Patients diagnosed as having BPH based on 
the standard "Guidelines for Diagnosis and 
Treatment of Urological Diseases of China (2014 
version)" [11]; (2) Patient who presented 
evidence of PKRP, and agreed to be treated 
surgically; (3) Patients who did not receive anti-
androgen drugs for the treatment of BPH within 
the previous 6 months; (4) Patients who had 
been informed of this study and had signed the 
"Informed Consent". All those who satisfied these 
criteria were accepted as subjects in this study. 
 
Exclusion criteria  
 
(1) Patients with uncorrected hypertension and 
diabetes; (2) Patients with abnormality in four 
blood coagulation indices; (3) Patients with 
unstable bladder; (4) Patients allergic to related 




Patients in the two groups were operated by the 
same surgeon, and sustained epidural 
anesthesia was used. The Gyrus bipolar plasma 
continuous irrigation resectoscope with a cutting 
power of 200W and electrocoagulation power of 
100W was used as the main equipment. Normal 
saline was used as irrigation fluid. The 
resectoscope was inserted into the urethra. The 
urethra, prostate and surrounding tissue 
morphology were first examined. The resection 
was carried out from the median lobe or the 
lateral lobe of the prostate, guided by the bladder 
neck and colliculus seminalis. The depth of the 
resection reached the circular fiber of the 
prostate capsule. Post-operative conventional in-
dwelling catheter was used. The high-dose group 
received 10mg of finasteride (Liaoning Yuhuang 
Pharmaceutical Co., Ltd.; SFDA approval no: 
H20061299; 5 mg/tablet) twice daily continuously 
at 7 days before and 7 days post-surgery. The 
low-dose group received 5 mg finasteride daily 
continuously at 7 days before and 7 days after 







These include operation time, intra-operative 
blood loss, weight of resected prostate, the 
amount of bleeding per unit of resected tissue, 
bleeding rate, amount of intraoperative rinsing 
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fluid (where the amount of bleeding per unit 
tissue = intraoperative blood loss/weight of 
resected prostate), and bleeding rate 




The international prostate symptom score (IPSS) 
[12] and the maximum urinary flow rate of 
patients in the two groups were measured at 7 
days before and after surgery. 
 
Changes in PSA and inflammatory factors 
 
The peripheral blood and prostatic fluid of the 
patients were collected before the first 
administration of finasteride, at 7 days before the 
surgery and after the last administration of the 
drug, and at 7 days after the surgery. The levels 
of serum PSA were measured by enzyme-linked 
immunosorbent assay (ELISA), using assay kits 
(American DPC (USA). Radioimmunoassay was 
employed to determine levels of TNF-α and IL-1β 
in prostatic fluid using an assay kit (Beijing North 
Institute of Biological Technology (China). Re-
bleeding situations after surgery were 




Data obtained were expressed as mean ± 
standard deviation, and were tested for 
significance by paired t- test, one-way analysis of 
variance (ANOVA) and SNK-q test. The analyses 
were done with SPSS 19.0 software. Constituent 
ratios were tested by chi-square test. Correlation 
analysis was performed by Pearson method. 
Differences between mean values were 




Baseline data for the three groups 
 
There were no significant differences in baseline 
data such as age, prostate volume, maximum 
urinary flow rate and underlying disease 
complications among the three groups (p > 0.05). 
These baseline data were comparable as shown 
in Table 1. 
 
Surgical results  
 
The weight of resected prostate and bleeding 
rate among the three groups showed no 
statistically significant differences (p > 0.05). 
Intraoperative blood loss, blood loss per unit 
resected tissue and the amount of intraoperative 
rinsing fluid were significantly lower in the high- 
and the low-dose group than those in the control 
group (p < 0.05). In addition, the operation time 
was significantly shorter in the high-dose group 
than that in the control group (p < 0.05), but there 
was no significant difference in these indices 
between the high- and the low-dose group (p > 
0.05; Table 2). 
 
Table 1: Baseline data for the three experimental groups (mean ± SD) 
 




Complicated with underlying diseases  
Hypertension Coronary heart disease Diabetes 
High-dose (47) 67.15±5.51  57.16±11.97 6.83±2.17 15（31.91%） 8（17.02%） 12（25.53%） 
Low-dose (47) 66.32±6.12 58.55±9.72 6.55±2.36 12（25.53%） 10（21.28%） 10（21.28%） 
Control (47) 68.68±5.86 56.23±9.54 7.11±1.95 16（34.04%） 10（21.28%） 12（25.53%） 
F/χ2 1.980 0.586 0.783 0.870 0.357 0.310 
P 0.142 0.558 0.459 0.647 0.837 0.856 
 

























High-dose (47) 52.19±14.49* 99.38±12.30* 28.19±4.34 3.00±1.74* 1.86±0.74 17.11±4.96* 
Low-dose (47) 52.79±15.30* 100.94±15.50* 28.42±4..44 3.48±1.86* 1.60±0.80 17.11±7.16* 
Control (47) 81.89±18.67 148.66±21.69 28.62±5.15 5.81±2.56 1.64±0.83 23.06±5.16 
F 51.269 128.346 0.099 24.548 1.466 16.248 
p 0.000 0.000 0.906 0.000 0.234 0.000 
 * p < 0.05, compared with the control group 
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Clinical efficacy  
 
The IPSS scores of all the patients at 7 days 
after surgery were significantly lower than those 
at 7 days before surgery, and the maximum flow 
rate at 7 days after the surgery was significantly 
higher than that at 7 days before the surgery; the 
inter-group difference was statistically significant 
(p < 0.05). The difference in IPSS scores and the 
maximum flow rate at 7 days before the surgery 
among three groups showed no statistical 
significance (p > 0.05). The IPSS scores of the 
high- and the low-dose group were significantly 
lower than those of the control group and the 
maximum flow rate was significantly higher than 
that of the control group at 7 days after the 
surgery (p < 0.05), but the difference between 
the high- and low-dose groups showed no 
statistically significance (p > 0.05; Table 3). 
 
Changes in PSA, TNF-α and IL-1β 
 
The PSA in serum, and levels of TNF-α and IL-
1β in prostatic fluid were significantly decreased 
among three groups at 7 days after surgery (p < 
0.05). The PSA in serum, and the levels of TNF-
α and IL-1β at 7 days before the surgery were 
not significantly different among the three groups 
(p > 0.05). The level of PSA in serum and TNF-α 
and IL-1β at 7 days after the surgery in the high-
dose group were the lowest, followed by the low-
dose group, while the levels in the control group 
were the highest. The PSA values, and levels of 
TNF-α and IL-1β in the high- and low-dose 
groups 7 days after surgery were statistically 
significantly different from each other (p < 0.05, 
Table 4). 
 
Correlation analysis of PSA in serum, TNF-α 
and IL-1β in prostatic fluid and IPSS scores 
 
Data obtained from 141 patients before and after 
surgery were included in this analysis. Pearson 
correlation analysis showed that PSA in serum, 
TNF-αand IL-1β in prostatic fluid were 
significantly positively correlated with IPSS 
scores (r = 0.817, 0.838, 0.859; all p < 0.001). 
The scattergrams showing the lines of best fit are 
shown in Figure 1. 
 
Admission rate due to re-bleeding within 3 
months post-surgery  
 
There were 2, 8 and 18 cases in the high-dose 
group, low-dose group and control group, 
respectively, due to re-bleeding within 3 months 
after surgery. The hospitalization rates were 
4.26, 17.02 and 38.30 %, respectively. The rate 
of re-bleeding in the high-dose group was 
significantly lower than that of the other two 
groups (χ2 = 4.100, 16.929; p < 0.05), while the 
rate of re-bleeding in the low-dose group was 
significantly lower than that of the control group 




Hemorrhage is the main complication of PKRP 
[13,14]. The intraoperative blood loss of the three 
groups   in   this   study  were  99.38  ±  12.30 ml, 
 
Table 3: Clinical efficacy of treatment in the three groups (mean ± SD) 
 
Group  
IPSS score Maximum flow rate (ml/s) 
7 days before 
surgery 
7 days after 
surgery 
7 days before 
surgery 7 days after surgery 
High-dose group (47) 24.23±6.59 6.68±1.49*# 6.59±1.75 28.47±4.78*# 
Low-dose group (47) 23.96±4.56 6.26±1.86*# 6.05±1.57 29.14±4.94*# 
Control group (47) 24.87±5.7 7.98±1.44# 6.50±1.44 23.53±4.23# 
F 0.329 14.678 1.583 20.297 
P 0.720 0.000 0.209 0.000 
Note: *Compared with the control group, p < 0.05; #compared with that at 7 days before surgery, p < 0.05 
 
Table 4: Changes in PSA, TNF-αand IL-1β for the three groups (mean ± SD) 
 










7 days after 
surgery 
7 days before 
surgery 
7 days after 
surgery 
High-dose (47) 10.06±1.29 2.67±0.53*#△ 66.05±17.26 3.24±0.50*#△ 4.33±0.45 0.79±0.12*#△ 
Low-dose (47) 10.17±1.05 3.41±0.38*# 69.24±15.97 4.66±0.54*# 4.24±0.36 1.21±0.08*# 
Control (47) 10.02±1.22 5.41±0.77# 67.60±16.25 8.40±1.32# 4.24±0.25 1.46±0.15# 
F 0.186 279.479 0.440 436.308 0.949 359.377 
p 0.831 0.000 0.645 0.000 0.390 0.000 
*Compared with the control group, p < 0.05; △compared with low-dose group, p < 0.05; #compared with that at 7 
days before surgery, p < 0.05 
 




Figure 1: Scattergram of IPSS scores and PSA in serum, TNF-αand IL-1β in prostatic fluid 
 
100.94 ± 15.50 ml, and 148.66 ± 21.69 ml 
respectively, which are smaller in volume when 
compared to the intraoperative blood loss 
reported by Zhouliang et al [15] and Xiaowei et al 
[16]. 
 
The values they reported were 210.45 ± 19.17 ml 
and 231.38 ± 77.52 ml respectively. The causes 
of bleeding include bladder spasm, incomplete 
hemostasis and residual glands [17], which 
cannot be completely avoided even with 
improved surgical skills. Hence there is need to 
take auxiliary measures that will ensure that 
bleeding is prevented completely or in the event 
of re-bleeding, that it is reduced to the barest 
minimum.  
 
Multiple studies [18,19] have revealed that 
treatment of patients with finasteride 
perioperatively helps to reduce intraoperative 
and post-operative blood losses. The results of 
this study were in accord with the earlier findings 
[18,19]. Finasteride at the doses used in the 
present study (5 mg/day or 10 mg/day) can 
reduce the intraoperative blood loss and blood 
loss due to tissue excision. Due to the low blood 
loss, the operative field was clearer, which 
accounted for the fact that the operation times in 
the high and high-dose groups were significantly 
shorter than that of the control group. This is 
consistent with the result obtained by Liuyu et al 
[20]. 
 
The protective effect of finasteride on 
intraoperative bleeding could be attributed to its 
inhibitory effect on the activity of vascular 
endothelial growth factor: androgens have 
stimulatory effect on vascular endothelial growth 
factor, and can increase prostate blood flow [21]. 
Finasteride can, by selectively and competitively 
inhibiting 5α reductase type II, block testosterone 
conversion to dihydrotestosterone (DHT). This 
reduces the level of active androgen, and is 
accompanied by reduced prostate blood flow. A 
previous report [22] also showed that finasteride 
can directly reduce the level of vascular 
endothelial growth factor (VEGF) in the kidney 
and the microvessel density. 
 
However, finasteride has other mechanisms of 
action on BPH. For example, Wuchengzhang et 
al [23] found that finasteride when administered 
to elderly patients with BPH can reduce the 
levels of serum TNF-α and PSA, which explained 
the fact that treatment with finasteride can relieve 
systemic inflammation and overexpression of 
PSA. It further shows that treatment of patients 
with finasteride in perioperative period can also 
reduce the levels of PSA and inhibit 
inflammation. The present study found that the 
PSA in serum, TNF-α and IL-1β in the high-dose 
groups were significantly lower than that of the 
control group, which gives credence to the 
foregoing hypothesis, and also lends weight to 
the view that finasteride when combined with 
PKRP can be the best and safest strategy for the 
management/ treatment of BPH. 
 
Current studies on the use of finasteride in 
perioperative period for the reduction of bleeding 
in BPH surgery are yet to be conclusive. There 
are differences in the doses and duration of use 
in various reports. For example, Shenjun et al 
[24] holds the opinion that finasteride should be 
used for a long time before surgery while 
Dengguangpeng et al [25] believe that treatment 
with high-dose of finasteride at 7 days before 
surgery could improve the surgical outcome. On 
the basis of the foregoing opinions and the 
findings from this study it does appear that: (a) 
surgery may not produce complete curative 
effect on BPH, and (b) continuous application of 
finasteride after surgery may enhance the 
curative effect.  
 
Thus, finasteride was applied 7 days before and 
after surgery, both in low and high-dose group in 
this study, and the results confirmed that the two 
Liu et al 
2995 
 
regimens improved the surgical outcome: the low 
levels of PSA and inflammatory factor observed 
in the high-dose group are remarkable, and 
suggest that this treatment strategy can bring 
about improved BPH prognosis. The low rate of 
re-bleeding admission after surgery as found in 
this study in the high-dose group is also 
indicative of better prognosis, which is consistent 
with previous reports [26,27]. 
 
Limitations of the study          
 
The sample size in this study is limited. 
Furthermore, the effect of the specific 
mechanism action of different doses of 
finasteride on PSA, TNF-α and IL-1β levels in 
BPH patients after PKRP is yet to be elucidated. 
Therefore, randomized trials based on a larger 




Finasteride, when combined with PKRP in the 
treatment of BPH further reduces serum PSA 
and local inflammatory factors. The effect is more 
pronounced in patients treated with higher dose 
of finasteride. The combination therapy is thus a 
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